Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: A pilot investigation with preliminary results

Experimental and Toxicologic Pathology

Volumn 54, Issue 5-6, 2003, Pages 475-479

  Merkel, Ute ^a   Wedding, Ulrich ^a   Roskos, Martin ^a   Höffken, Klaus ^a   Hoffmann, Annemarie ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Chronomodulated infusion; Oxaliplatin; Pharmacokinetics

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG METABOLISM; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; MALE; METASTASIS; PILOT STUDY; SAMPLE SIZE; ULTRAFILTRATION;

EID: 0038234812     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00283     Document Type: Article

References (26)

1. ALLEN J, GRAHAM MA, FIRTH J, et al.: Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer. Proc Am Assoc Cancer Res 1998; 39: 159.
2. BERTHEAULT-CVITKOVIC F, JAMI A, ITHZAKI M, et al.: Bi-weekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950-2958.
3. FALCONE A, ALLEGRINI G, MASI G, et al.: 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. Oncology 2001; 61: 28-35.
4. FALCONE A, MASI G, ALLEGRINI G, et al.: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006-4014.
5. GAMELIN E, BOUIL AL, BOISDRON-CELLE M, et al.: Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 1997; 3: 891-899.
6. GIACCHETTI S: Chronotherapy of colorectal cancer. Chronobiol Int 2002; 9: 207-219.
7. GIACCHETTI S, PERPOINT B, ZIDANI R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Clin Oncol 2000; 18: 136-147.
8. GRAHAM MA, GAMELIN E, MISSET JL, et al.: Clinical pharmacokinetics of oxaliplatin. Proc Am Assoc Cancer Res 1998; 39: 159.
9. GRAHAM MA, LOCKWOOD GF, GREENSLADE D, et al.: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000; 6: 1205-1218.
10. GRANDA TG, LEVI F: Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol Int 2002; 19: 21-41.
11. HARRIS BE, SONG R, SOONG SJ, et al.: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
12. HEINZEL G, WOLOSZCZAK R, THOMANN P: Topfit Version 2.0: pharmacokinetic and pharmacodynamic data analysis system for PC. Dr. Karl Thomae GmbH Stuttgart 1993.
13. JUNKER AM, PIECK AC, WEHMEIER A, et al.: Interindividual differences in oxaliplatin pharmacokinetics. Int J Clin Pharmacol Ther 2002; 40: 569-570.
14. KERN W, BRAESS J, BOTTGER B, et al.: Oxaliplatin pharmacokinetics during a four-hour infusion. Cancer Res 1999; 5: 761-765.
15. LEVI F, METZGER G, MASSARI C, et al.: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38: 1-21.
16. LEVI F, ZIDANI R, BRIENZA S, et al.: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer 1999; 85: 2532-2540.
17. LEVI F, ZIDANI R, MISSET JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997; 350: 681-686.
18. LEVI FA, ZIDANI R, VANNETZEL JM, et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-1617.
19. LIU J, KRAUT E, BENDER J, et al.: Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol 2002; 49: 367-374.
20. LUO FR, WYRICK SD, CHANEY SG, et al.: Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res 1998; 10: 595-603.
21. MASSARI C, BRIENZA S, ROTARSKI M, et al.: Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 2000; 45: 157-164.
22. METZGER G, MASSARI C, ETIENNE MC, et al.: Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther 1994; 56: 190-201.
23. METZGER G, MASSARI C, RENEE N, et al.: Variations in platinum (Pt) plasma levels depending on chronomodulated oxaliplatin (I-OHP) peak time. Proc Am Soc Clin Oncol 1997; 16: 863.
24. RAIDA M, SCHWABE W, HAUSLER P, et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832-2839.
25. REPPERT SM, WEAVER DR: Coordination of circadian timing in mammals. Nature 2002; 418: 935-941.
26. WINNEFELD K, SCHRÖTER H: Bestimmung des Platins im Serum mittels Graphitrohr-AAS 4. Applikationsschriften zur AAS 1992. Zeiss Jena, Germany.